SRC and cancer: The aberrant expression of MUC1 has been well documented in various cancers and is correlated with advanced tumor progression and metastasis potential; furthermore, several fundamental works revealed that MUC1-C may function as an oncogene in the progression of cancers by interacting with many biological molecules, such as ICAM-1, β-catenin, EGFR, c-Src, and p65, to promote cell motility, adhesion, proliferation, and survival [14–17].